Description of Invention: Overall cancer costs in the U.S. in 2006 are estimated at $206.3 billion. The World Health Organization predicts upwards of 15 million new cancer cases globally by 2020. There remains a significant unmet need for new therapies to treat cancer, as well as a need to further understand the role of the immune system in cancer susceptibility.
Available for licensing are isolated immunoglobulin-producing mouse plasmacytomas (PCTs). Each tumor produces only one species of monoclonal immunoglobulin (Ig). When transplanted into mice, these plasma cell tumors will continue to produce only the same unique Ig molecules. Some (5-10%) of the Igs specifically bind antigens.
Applications:
To understand the underlying process of neoplastic development
To identify the genes that control tumor susceptibility and resistance
To investigate the antigen binding activities of myeloma proteins
To study Ig synthesis
To classify the various different classes of Igs (IgG, IgA, IgM)
As a fusion partner to make monoclonal antibodies
Advantages: Provide an unlimited source of pure monoclonal Ig molecules
Inventors: Michael Potter (NCI)
Patent Status: HHS Reference No. E-277-2001/0 – Research Material. Patent protection is not being pursued for this technology.
Relevant Publication:
Potter M, Fahey JL, Pilgrim HI. Abnormal serum protein and bone destruction and transmissible mouse plasma cell neoplasm (multiple myeloma). Proc Soc Exp Biol Med. 1957 Feb;94(2):327-333.
Nathans D, Fahey JL, Potter M. The formation of myeloma protein by a mouse plasma cell tumor. J Exp Med. 1958 Jul 1;108(1):121-130. [ PubMed: 13549645 ]
Potter M, Boyce CR. Induction of plasma cell neoplasms in strain BALB/c mice with mineral oil and mineral oil adjuvants. Nature. 1962 Mar 17;193:1086-1087.
Andersen PN, Potter M. Induction of plasma cell tumors in BALB/c mice with 2,6,10,14-tetramethylpentadecane (pristane). Nature. 1969 Jun 7;222(5197):994-995.
Licensing Status: Available for biological materials licensing only.
Portfolios: Cancer Cancer - Research Materials
For Licensing Information Please Contact: Patrick McCue Ph.D. NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325, Rockville, MD 20852 United States Email: McCuepat@mail.nih.gov Phone: 301-496-7057 Fax: 301-402-0220
Description of Invention:
Overall cancer costs in the U.S. in 2006 are estimated at $206.3 billion. The World Health Organization predicts upwards of 15 million new cancer cases globally by 2020. There remains a significant unmet need for new therapies to treat cancer, as well as a need to further understand the role of the immune system in cancer susceptibility.
Available for licensing are isolated immunoglobulin-producing mouse plasmacytomas (PCTs). Each tumor produces only one species of monoclonal immunoglobulin (Ig). When transplanted into mice, these plasma cell tumors will continue to produce only the same unique Ig molecules. Some (5-10%) of the Igs specifically bind antigens.
Applications:
Advantages:
Provide an unlimited source of pure monoclonal Ig molecules
Inventors:
Michael Potter (NCI)
Patent Status:
HHS Reference No. E-277-2001/0 – Research Material. Patent protection is not being pursued for this technology.
Relevant Publication:
Licensing Status:
Available for biological materials licensing only.
Portfolios:
Cancer
Cancer - Research Materials
For Licensing Information Please Contact:
Patrick McCue Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Email: McCuepat@mail.nih.gov
Phone: 301-496-7057
Fax: 301-402-0220
Ref No: 2221
Updated: 01/2011